Join Conscio Group upcoming webinar on December 12 at 2:00 PM CET (expected length up to 2 hours), where industry experts will discuss the latest trends in regulation, R&D and clinical testing. In our session we will particularly explore potential regulatory changes regarding the waiver of Phase 3 efficacy studies.

Topics include:

  • Navigating Biosimilar Regulations: Evolution, Challenges, and Future Directions
  • Common pitfalls on the path from R&D to biotech product commercialization
  • Strategies for successful bioassay transfer and validation – the importance of standardization

Speakers: Elena Guillen Benitez, MD, PhD from Leiden University Medical Center, Martin Baur from Midas Pharma, and Klemens Weitenthaler from Conscio Group.

Moderator: Stephan Holl, CEO Conscio Group

Gain insider knowledge on the biosimilar industry – register here!

If you would like to view the recording of the webinar, please contact us today and we will be happy to give you exclusive access to it on our YouTube channel.

Additional News

  • 11 September 2025

    Meet us at CPHI 2025

    This October, the global pharmaceutical community will gather in Frankfurt for CPHI 2025. Quinta-Analytica as a member of Conscio Group will be there too – visit us in the Contract Manufacturing Hall 5.1, Stand F1.

  • 8 September 2025

    Quinta-Analytica successfully passed two onsite FDA inspections

    In the first half of 2025, Quinta-Analytica underwent two onsite inspections by the U.S. Food and Drug Administration (FDA).

  • 21 July 2025

    Boosting Bioanalytical Power for our clients

    New ICP-MS Expands Our Capabilities

ALL POSTS